Loss of Calpain-3 Autocatalytic Activity in LGMD2A Patients with Normal Protein Expression

Marina Fanin,* Anna Chiara Nascimbeni,* Luigi Fulizio,* Carlo Pietro Trevisan,* Marija Meznaric-Petrusa,† and Corrado Angelini*  
From the Department of Neurological and Psychiatric Sciences,* University of Padova, Padova, Italy, and the Institute of Anatomy,† University of Ljubljana, Ljubljana, Slovenia

The diagnosis of limb girdle muscular dystrophy (LGMD) type 2A (due to mutations in the gene encoding for calpain-3) is currently based on protein analysis, but mutant patients with normal protein expression have also been identified. In this study we investigated 150 LGMD patients with normal calpain-3 protein expression, identified gene mutations by an allele-specific polymerase chain reaction test, and analyzed the mutant calpain-3 catalytic activity. Four different mutations were found in eight patients (5.5%); a frame-shifting deletion (550 A del) and three missense (R490Q, R489Q, R490W). Patients with normal calpain-3 protein expression on Western blot are a considerable proportion (20%) of our total LGMD2A population. While in control muscle the calpain-3 Ca++-dependent autocatalytic activity was evident within 5 minutes and was prevented by ethylene diaminetetraacetic acid, in all mutant patient samples the protein was not degraded, indicating that the normal autocatalytic function had been lost. By this new functional test, we show that conventional protein diagnosis fails to detect some mutant proteins, and prove the pathogenetic role of R490Q, R489Q, R490W missense mutations. We suggest that these mutations impair protein activity by affecting interdomain protein interaction, or reduce autocatalytic activity by lowering the Ca++ sensitivity. (Am J Pathol 2003, 163:1929–1936)

Autosomal recessive limb girdle muscular dystrophies (LGMD type 2) are a clinically and genetically heterogeneous group of disorders, characterized by progressive involvement of proximal limb girdle muscles. LGMD2A (MIM number 253600), whose locus has been mapped to chromosome 15q15.1,1 is considered to be the most frequent form of recessive LGMD. LGMD2A is caused by single or small nucleotide changes widespread along a 40-kb gene, named CAPN-3.2 More than 110 different CAPN-3 gene mutations have been described3–10, about 45% are null mutations and half are missense.

LGMD2A is caused by defects in a protein with an enzymatic rather than structural function. CAPN-3 gene encodes for calpain-3 (originally named p94), the muscle-specific member of a family of Ca+++-activated neutral proteases, which also includes the ubiquitous m- and μ-calpains. Calpain-3 is a multidomain protein, characterized by 3 exclusive sequence inserts (NS, IS1, IS2)11; domain I has regulatory role, domain II is the proteolytic module, domain III has a C2-domain like Ca+++-binding function (probably involved in Ca+++-dependent translocation of calpain to the membrane), and domain IV binds Ca++ ions.

The pathological consequences of CAPN-3 gene mutations have been investigated on both protein and clinical phenotype: patients homozygous for null mutations usually have severe phenotype and absent protein, whereas patients homozygous for missense mutations have variable protein amount and disease severity.3,4,9 Moreover, the same mutation can produce a wide varia-
tion at both the clinical and protein level (from normal to absent). Recently, the diagnosis of LGMD2A has been based on protein testing, but only patients who show a deficiency are selected for subsequent mutation screening. This approach is useful for diagnosing previously undetermined LGMD patients, but it is not completely sensitive; some patients with normal protein expressions do have CAPN-3 gene mutations. The functional characterization of CAPN-3 gene mutations could be helpful in explaining why some missense mutations lead to the synthesis of a protein that loses its function but preserves normal expression. The only functional studies were conducted by site-directed mutagenesis on animal cultured cells or transgenic mice and demonstrated that some mutants lost autocalytic activity, while others lost fodrinolytic capacity.

In this study we investigated a group of LGMD2A patients who showed normal calpain-3 protein expression to identify CAPN-3 mutant alleles and, further, characterized the function of the resulting abnormal protein by biochemical assays.

Materials and Methods

Patients

Our muscle biopsy bank contains more than 5300 specimens which have been collected since 1980 for diagnostic purposes. Reviewing the diagnosis of all samples, about 20% of total (1100) were classified as "muscular dystrophy" on the basis of clinical, histopathological, and molecular findings. For the purpose of this study, we excluded 644 muscular dystrophy biopsies because our multiple-protein screening (for dystrophin, dystroglycan, dysferlin, calpain-3, caveolin-3, merosin, and emerin) identified one deficient protein and/or a molecular diagnosis was assessed (199 DMD, 164 BMD, 50 D/BMD carrier, 34 LGMD2A, 33 LGMD2B, 19 LGMD2D, 7 LGMD2C, 6 LGMD2E, 1 LGMD2F, 9 LGMD1C, 3 EDMD1, 22 merosin-deficient congenital dystrophy, 71 myotonic dystrophy, 26 facio-scapulo-humeral dystrophy). An additional 306 patients were excluded because their phenotype was considered not compatible with LGMD2A (dominant LGMD, distal myopathy, scapulo-peroneal dystrophy, oculo-pharyngeal dystrophy, and merosin-positive congenital dystrophy).

A total of 150 patients were selected for CAPN-3 mutation screening since they matched the following criteria: normal expression of above mentioned muscle proteins, muscle biopsy histopathology consistent with a dystrophic or myopathic process, and increased creatine kinase (CK) levels (> 500 U/L). Of these 150 patients, 129 were diagnosed as affected with LGMD, 18 with proximal myopathy, and three were presymptomatic with high CK.

The clinical severity of muscle disease was graded as 1) asymptomatic: elevated CK level, calf hypertrophy, cramps after effort; 2) mild: muscle weakness in lower and/or upper girdle; 3) moderate: waddling gait, Gowers’ sign, difficulty climbing stairs; and 4) severe: significant loss of muscle strength or loss of ambulation.

Muscle Biopsy Histopathology and Electron Microscopy

Microscopy inspection of routinely stained sections was used to determine the degree of the dystrophic/myopathic process, on the following graded scale: 1, active dystrophic process (marked increase of fiber size variability, active degeneration and regeneration, marked increase of connective tissue); 2, moderate dystrophic process (marked increase of fiber size variability, increased central nuclei, few degenerating and regenerating fibers, slight increase of connective tissue); and 3, mild myopathic picture (moderate increase of fiber size variability, increased central nuclei) (see examples of each category in Figure 1).

For electron microscopy, muscle tissue was fixed for 3 hours at 4°C in 5% glutaraldehyde buffered with 0.1 mol/L cacodylate buffer (pH 7.2), washed overnight at 4°C with cacodylate buffer with 0.1 mol/L sucrose, postfixed in 1% osmium tetroxid (Sigma, St. Louis, MO), dehydrated, infiltrated, and embedded in Epon 812 epoxy resin (Electron Microscopy Sciences, Fort Washington, PA). Longitudinal ultrathin sections were stained with uranyl acetate and lead nitrate and examined with a Jeol transmission electron microscope JEM-1200 EXII.

Immunoblot Studies

Western blot analysis was performed as described previously, with minor modifications. Briefly, muscle biopsy sections were dissolved in loading buffer (0.05 mol/L dithiothreitol, 0.1 mol/L ethylenediaminetetra-acetic acid (EDTA), 0.125 mol/L Tris, 4% sodium dodecyl sulfate (SDS), 0.005% bromphenol blue), boiled, and centrifuged. Proteins were resolved by SDS-PAGE and electroblotted to nitrocellulose membrane (Hoefer Pharmacia, San Francisco, CA). Post-transfer gels were stained with Coomassie blue, whereas the blots were blocked with bovine serum albumin (BSA) and then incubated with antibodies against calpain-3 (Calp12A2, diluted 1:800; Novocastra, Newcastle-upon-Tyne, UK), nebulin (1:400; Sigma), α-actinin (1:400; Novocastra), dystrophin (C-terminus, 1:1000; Novocastra), desmin (1:500; Novocastra), and β-dystroglycan (1:400; Novocastra). Immunoreactive bands were visualized using avidin-biotin peroxidase and chemiluminescent method (ECL; Amersham, Rainham, UK).

Biochemical Studies

Calpain-3 Autocatalytic Assay

Several sets of control muscle biopsy sections were dissolved in 50 µl of sterile saline solution and incubated at room temperature for different lengths of time (0, 1, 5, 10, 20, and 30 minutes) before further adding 50 µl of...
loading buffer. To conserve muscle tissue, the same experiment was conducted on patient samples for only 5 and 20 minutes of incubation, on the basis of the results obtained in the controls. To test the role of Ca\(^{++}\) ions in calpain-3 autocatalytic activity, an additional set of sections was incubated in saline solution with 10 mmol/L EDTA. All samples were then processed as described for immunoblot analysis, using antibodies against calpain-3.

**Calpain-3 Proteolytic Assay**

The role of time-dependent calpain-3 proteolytic activity on several muscle proteins (dystrophin, β-dystroglycan, α-actinin, desmin, and nebulin) has been tested by immunoblot on muscle samples in the experimental condition described for calpain-3 autocatalytic assay; multiple loading of each sample was used, followed by labeling with different antibodies.

**Molecular Studies**

**DNA Extraction**

Genomic DNA was extracted from blood leukocytes or muscle biopsy, using GenElute Mammalian Genomic DNA kit and the procedure recommended by the manufacturer (Sigma). DNA concentration and integrity were tested by optical density measurement and by 0.8% agarose gel electrophoresis, respectively. A working dilution of 100 ng/µl DNA sample was prepared.

**PCR Amplification with Allele-Specific Primers**

Fifteen different CAPN-3 gene mutations were selected for our allele-specific screening on the basis of their frequency or because they were expected to result in normal protein expression.\(^8,12,14,23,26\) Selected mutations have been previously reported in other patients, and the possibility that they were polymorphic variants was excluded.\(^4\) Seven mutations (550 del. A, G222R, R448H, R489W, R572Q, R748Q) were studied using classic ARMS-PCR test (Amplification Refractory Mutation System), and eight mutations (D77N, T184, R448C, R489Q, R490W, G496R, S606L) using tetra-primer ARMS-PCR.\(^27\) In the latter method, one pair of outer control primers and one pair of inner primers (specific for mutant and wild-type alleles) are used in the same reaction. By positioning the outer primers at different distances from mutation point, two different small allele-specific and one large control PCR products are produced. To enhance the allelic specificity, a second deliberate mismatch at position −2 from the 3′ terminus was incorporated in the inner primers, according to the rules described by Little.\(^28\)

We choose this method because of its high specificity and rapidity, and because it provides an internal control reaction that reduces false negative results. The primer sequences used for ARMS were those reported elsewhere,\(^4\) except one for R448H. The primers for this mutation by ARMS and for tetra-primer ARMS (sequence available on request) were designed using Primer soft-

---

**Figure 1.** Muscle biopsy sections stained with trichrome (a) and hematoxylin and eosin routine stains (b to d). In the “active stage dystrophic process” (a and b) increased fiber size variability, fibro-fatty replacement, and degenerating and regenerating fibers are observed. “Moderate dystrophic process” (c) is characterized by increased fiber size variability, central nuclei, regenerating, and ring fibers. “Mild myopathic process” (d) shows slight fiber size variability and central nuclei. Magnification, ×400.
Table 1. Clinical and Molecular Data

<table>
<thead>
<tr>
<th>Patient, sex</th>
<th>Family history</th>
<th>Age at onset (years)</th>
<th>Age at biopsy (years)</th>
<th>CK at biopsy (U/L)</th>
<th>Muscle pathology severity</th>
<th>Clinical grade at biopsy</th>
<th>Clinical grade at last exam</th>
<th>Nucleotide change</th>
<th>Amino acid change</th>
<th>Exon</th>
<th>Zygosity</th>
<th>Mutation type</th>
</tr>
</thead>
<tbody>
<tr>
<td>1, M</td>
<td></td>
<td>17</td>
<td>29</td>
<td>1603</td>
<td>Active</td>
<td>Severe</td>
<td>Severe (46)</td>
<td>G1469A</td>
<td>R490Q</td>
<td>11</td>
<td>Homoz.</td>
<td>Missense</td>
</tr>
<tr>
<td>2, F</td>
<td>+</td>
<td>28</td>
<td>30</td>
<td>783</td>
<td>Active</td>
<td>Moderate</td>
<td>Severe (36)</td>
<td>G1469A</td>
<td>R490Q</td>
<td>11</td>
<td>Homoz.</td>
<td>Missense</td>
</tr>
<tr>
<td>3, M*</td>
<td></td>
<td>37</td>
<td>43</td>
<td>4348</td>
<td>Mild</td>
<td>Mild</td>
<td>Mild (49)</td>
<td>G1469A</td>
<td>R490Q</td>
<td>11</td>
<td>Homoz.</td>
<td>Missense</td>
</tr>
<tr>
<td>4, M*</td>
<td></td>
<td>10</td>
<td>10</td>
<td>5680</td>
<td>Mild</td>
<td>Asymptomatic</td>
<td>Moderate (26)</td>
<td>G1469A</td>
<td>R490Q</td>
<td>11</td>
<td>Heteroz.</td>
<td>Missense</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td>11</td>
<td>16</td>
<td>3200</td>
<td>Mild</td>
<td>Asymptomatic</td>
<td>–</td>
<td>G1466A</td>
<td>R489Q</td>
<td>11</td>
<td>Heteroz.</td>
<td>Missense</td>
</tr>
<tr>
<td>6, M</td>
<td></td>
<td>20</td>
<td>20</td>
<td>5200</td>
<td>Moderate</td>
<td>Mild</td>
<td>Mild (26)</td>
<td>G1469A</td>
<td>R490Q</td>
<td>11</td>
<td>Heteroz.</td>
<td>Missense</td>
</tr>
<tr>
<td>8, M</td>
<td></td>
<td>16</td>
<td>21</td>
<td>8600</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate (30)</td>
<td>C1468T</td>
<td>R490W</td>
<td>11</td>
<td>Heteroz.</td>
<td>Missense</td>
</tr>
</tbody>
</table>

*, second-degree cousins; †, only one mutant allele was found.

PCR Amplification of Genomic DNA Sequence and DNA Sequencing

For DNA sequence analysis, the genomic sequence of exons 4 and 11 (the only exons where mutations were found) were amplified as described above. For exon 4, we used the primer sequence reported elsewhere, whereas for exon 11 the primer sequences used were: forward 5′-TGTAGGGAATAGAATAAATGG-3′; reverse 5′-CCAGGAGTCTGTGGGTCA-3′. PCR products were purified using the Microcon Amicon PCR kit (Millipore, Bedford, MA), quantified on agarose gel, and directly sequenced in both directions using the Big Dye dideoxynucleotide cycle sequencing kit and the ABI-PRISM model 377 automated sequencer (Applied Biosystems), at the CRIBI Biotechnology Center (http://bmr.criibi.unipd.it), University of Padova. Sequence analysis was obtained using Chromas 1.45 software (http://www.technelysium.com.au/chromas.html).

Results

Patients

Our ARMS screening detected mutations in the CAPN-3 gene in 8 patients with normal calpain-3 protein expression (Table 1). All patients presented an LGMD phenotype, and they had a variable age of onset (from 10 to 37 years) and different degree of clinical severity at biopsy. Their clinical follow-up showed that the disease progression was widely variable, even between the 4 patients homozygous for the same missense R490Q mutation (Table 1).

Morphological Features

We observed by histopathological analysis that patients 1 and 2 presented an active dystrophic process (Figure 1, a and b, respectively) with clusters of regenerating and degenerating fibers, while patients 6 to 8 had a moderate dystrophic process (Figure 1c, patient 6), and patients 3 to 5 revealed a mild myopathic picture (Figure 1d, patient 3). There was a correlation between the severity of muscle histopathology and the clinical phenotype: patients with an active dystrophic process had severe form of muscular dystrophy, whereas patients with mild pathological changes showed a slowly progressive myopathy (Table 1). The normal expression of several muscle-specific proteins indicates that the primary calpain-3 defect does not affect the integrity of either the plasma or the...
nucleotide changes.

The right-hand figure shows direct DNA sequence analysis in patient 6: the wild-type (w) and the mutant (m) alleles. Patients 6 and 7 are heterozygote. The middle figure shows the results for the R489Q mutation: normal control (C) and patients 1 to 6 are tested for the R489Q mutation; the amplification pattern of the wild-type allele (176 bp), the mutant allele (194 bp) and the outer primer amplicon (315 bp) indicates that patient 5 is heterozygous. The middle figure shows the results for the R489Q mutation: normal control (C) and patients 1 to 6 are tested for the R489Q mutation; the amplification pattern of the wild-type allele (176 bp), the mutant allele (194 bp) and the outer primer amplicon (315 bp) indicates that patient 5 is heterozygous. The right-hand figure shows the results for the R490W mutation: normal control (C) and patients 1 to 6 are tested for the R490W mutation; the amplification pattern of the wild-type allele (213 bp), the mutant allele (188 bp), and the outer primer amplicon (347 bp) indicates that patient 5 is heterozygous.

The left-hand figure shows the agarose gel electrophoresis for the 550 del. A mutation. Normal control (C), homozygous control (ho), heterozygous control (he), and patients 6 and 7 are tested for both the wild-type (w) and the mutant (m) alleles. Patients 6 and 7 are heterozygote. The right-hand figure shows direct DNA sequence analysis in patient 6: an arrow points to the mutation site (550 del. A) with the consequent frameshifting. B: The left-hand figure shows the agarose gel electrophoresis for the R490Q mutation: normal control (C) and patients 1 to 6 are tested for the wild-type (192 bp) and mutant alleles (168 bp) and the outer primer amplicon (304 bp). Patients 5 and 6 are heterozygous, and patients 1 to 4 are homozygous. The middle figure shows the results for the R490Q mutation: the amplification pattern of the wild-type allele (213 bp), the mutant allele (188 bp), and the outer primer amplicon (347 bp) indicates that patient 5 is heterozygous. The right-hand figure shows the results for the R490Q mutation: the amplification pattern of the wild-type allele (176 bp), the mutant allele (194 bp) and the outer primer amplicon (315 bp) indicates that patient 7 is heterozygous. Direct DNA sequence analysis in patients 5 (compound heterozygote for both R490Q and R490Q) and 7 (heterozygote for R490W) is shown in the bottom figure; arrows indicate the mutation sites and the nucleotide changes.

Figure 2, CAPN-3 gene mutation analysis by ARMS-PCR (A) and tetra-primer ARMS-PCR (B), and corresponding DNA sequence analysis. A: Left-hand figure shows the agarose gel electrophoresis of the 185-bp PCR products for the 550 del. A mutation. Normal control (C), homozygous control (ho), heterozygous control (he), and patients 6 and 7 are tested for both the wild-type (w) and the mutant (m) alleles. Patients 6 and 7 are heterozygote. The right-hand figure shows direct DNA sequence analysis in patient 6: an arrow points to the mutation site (550 del. A) with the consequent frameshifting. B: The left-hand figure shows the agarose gel electrophoresis for the R490Q mutation: normal control (C) and patients 1 to 6 are tested for the wild-type (192 bp) and mutant alleles (168 bp) and the outer primer amplicon (304 bp). Patients 5 and 6 are heterozygous, and patients 1 to 4 are homozygous. The middle figure shows the results for the R490Q mutation: the amplification pattern of the wild-type allele (213 bp), the mutant allele (188 bp), and the outer primer amplicon (347 bp) indicates that patient 5 is heterozygous. The right-hand figure shows the results for the R490Q mutation: the amplification pattern of the wild-type allele (176 bp), the mutant allele (194 bp) and the outer primer amplicon (315 bp) indicates that patient 7 is heterozygous. Direct DNA sequence analysis in patients 5 (compound heterozygote for both R490Q and R490Q) and 7 (heterozygote for R490W) is shown in the bottom figure; arrows indicate the mutation sites and the nucleotide changes.

CAPN-3 Gene Mutation Identification

Screening gene mutations by allele-specific primers allowed us to detect four different CAPN-3 gene mutations in eight of 150 patients (5.5%) (Table 1; Figure 2): an A deletion at position 550 (550 del. A) in 2 heterozygote patients; a C to T substitution at position 1468, causing an arginine to tryptophan amino acid change at position 490 (R490W) in two heterozygote patients; a G to A substitution at position 1466 causing an arginine to glutamine amino acid change at position 489 (R489Q) in one heterozygote patient; a G to A substitution at position 1469 causing an arginine to glutamine amino acid change at position 490 (R490Q) in four homozygote and two heterozygote patients (10 of 16 mutant alleles). All of the mutations found by ARMS were confirmed by sequence analysis. In one patient (8) this method allowed to detect only one mutant allele (Table 1). Two affected relatives (3 and 4) and a third unrelated patient (2) shared the same family name and a homozygous R490Q mutation (Table 1); though they were not aware of any parental consanguinity, a founder effect was suspected, because these patients came from the same town in the Venetian lagoon, in a region that in the past was genetically isolated.

Functional Characterization of Calpain-3 Protein

Immunoblot analysis for calpain-3 showed a normal protein expression in all mutant patients (Figure 3A). The study of autocatalytic calpain-3 activity has shown that in control muscle the full-length protein (94 kd) is degraded...
after 5 minutes, and the three typical degradation
bands of lower molecular weight (60, 58, 55 kDa)
appear progressively (Figure 3, A to C). On the other
hand, under the same experimental condition, the full-
length protein was still present at normal level in muscle
of all patients, indicating that the normal autocalytic
activity of calpain-3 was lost (Figure 3B). To check if
autocatalysis could occur in patients’ muscle with a
longer time, we incubated patient samples also for 20
minutes, and observed calpain-3 degradation as in con-
trol muscle (data not shown).

Calpain-3 autocatalytic activity was tested also in eight
different disease control muscle biopsies (3 DMD, 2 BMD,
1 LGMD2B, 1 LGMD1C, 1 LGMD2D): all patients showed
the marked reduction of 94 kDa calpain-3 protein band
and the appearance of degradation bands (Figure 3D).

Calpain-3 autocatalysis did not occur in control muscle
when 10 mmol/L EDTA was added (Figure 3C), indicating
that Ca²⁺ ions (contained in the saline solution) are
required for its normal function. A high molecular-weight
band (of about 800 kDa) was present in the posttransfer
Coomassie blue-stained gels of control and patient sam-
ples where calpain-3 autocatalysis was avoided, and it
progressively disappeared during autolysis (Figure 3A).
This band likely corresponds to a muscle-specific pro-
tein, possibly nebulin. Through immunoblot analysis,
nebulin was normally expressed in both control and pa-
tient samples when calpain-3 autocatalysis was avoided;
in the control muscle where calpain-3 autocatalysis oc-
curred nebulin amount was highly reduced (Figure 4).
Other muscle proteins, such as desmin, α-actinin, β-dys-
troglycan, and dystrophin were normally expressed dur-
ing time-dependent calpain-3 autocalytic activity (data
not shown).

Discussion

Since calpain-3 antibodies have been available for pro-
tein testing the diagnosis of calpainopathy has shifted
from molecular genetics toward biochemistry. Mutation
detection on multiple genes is not used as a first-line
diagnostic approach for unclassified LGMD patients, be-
cause of the high cost and effort required. The validity of
protein testing has been fully recognized as most pa-

tients with protein defect do indeed have CAPN-3
gene mutations. However, CAPN-3 mutant patients who
show normal protein expression have occasionally been
reported, and they represent a potential pitfall of using
only protein testing. In this study, we systematically
screened a large series of undiagnosed LGMD patients
with normal calpain-3 protein expression using an allele-
specific mutation test, and we have demonstrated that
this approach is effective in the detection of CAPN-3
gene mutations.

One important conclusion of this study is that conven-
tional calpain-3 protein screening fails to detect mutant
proteins in a considerable number of cases. We calcu-
lated that mutant cases expressing normal protein are
5.5% of unclassified LGMD cases in our study, but this
number would probably be higher if a complete gene
sequence analysis had been done. The importance of
the approach by allele-specific screening for diagnostic test-
ing is documented by the detection of an additional 20%
of primary LGMD2A patients in our population (8 of 42),
as 80% of cases have been identified by calpain-3 defi-
ciency on immunoblot. Thus, LGMD2A is more frequent
than would appear when calculated only from protein
testing, and in our population it accounts for about 19% of
all LGMD patients diagnosed so far. As linkage analysis
and genetic epidemiology from 85 LGMD brazilian fam-
ilies estimated that 30% of all LGMD cases are LGMD
type 2A, it seems likely that the same proportion would
result also in european countries if a complete CAPN-3
genotype analysis is done in all unclassified LGMD patients.
Following the molecular characterization of LGMD2A
patients by allele-specific test, we analyzed the mutant
calpain-3 activity. Another new result of our study is the
demonstration that the mutant protein was fully ex-
pressed in muscle tissue from a series of molecularly
proven LGMD2A patients, but it had lost its normal auto-
catalytic function.

Unlike muscular dystrophies where structural proteins
are involved, calpainopathy is the result of an enzyme
defect, where, as in enzymatic disorders, the mutant
protein may be inactive even if it is present. Diagnosing
LGMD2A, clinicians should be careful if they draw con-
clusions based on calpain-3 protein testing alone, unless
a functional protein test (such as autocalysis) has been
used as well. The availability of a simple method to test
calpain-3 autocalytic capacity in patients’ muscle offers
a novel diagnostic improvement. This test should be as-
associated with conventional calpain-3 protein studies to
select LGMD patients where Western blot analysis does
not reveal an etiology.

Earlier studies of site-directed mutagenesis suggested
that there might be a pathogenetic effect in some
CAPN-3 gene mutations in COS-7 cells, mouse muscle
cells13,14,24 or transgenic mice, but such studies
have not yet been done on human biopsies. In our study
the functional test was useful to demonstrate the patho-
genetic role of R490W, R490Q, and R489Q missense mutations in LGMD2A, which usually have unpredictable consequences at protein level. By comparison with ubiquitous calpains, these missense mutations could either be affecting intramolecular domain interaction, or be causing an alteration in the charge of side chains involved in internal salt links.\(^{12}\)

The Ca\(^{2+}\)-dependence of calpain-3 has been controversial, with some authors arguing that calpain-3 is Ca\(^{2+}\)-independent in vitro, while others have argued that it requires very low Ca\(^{2+}\) level concentration. In this study we offer indirect evidence that calpain-3 has Ca\(^{2+}\)-dependence: when Ca\(^{2+}\) ions were subtracted through the addition of EDTA to the incubation medium, normal autocatalytic activity is blocked.

Recent investigations in COS cells\(^{14}\) further suggested that some mutations (including the R490W) possibly affect interdomain protein interaction, resulting in a reduction of the autocatalytic activity by lowering Ca\(^{2+}\) sensitivity. The salt bridge region in domain III would exert a conformational constraint on the movement of domain IIb\(^{11}\); if mutations in domain III produce an altered Ca\(^{2+}\) requirement, the R490W, R490Q, and R489Q mutations described in this study (located in domain III) could have a similar effect on protein activity as well.

The characterization of CAPN-3 gene mutations and their corresponding effect on protein function makes it possible to draw up a kind of functional genetic map. To date, only few missense mutations have been reported to produce a normal expression of calpain-3 protein in LGMD2A patients: T184M and G222R (both in domain IIa)\(^8\) might disrupt domain IIa-domain IIb interaction\(^{12}\), G496R and S606L found in one compound heterozygote patient\(^{23}\) (both in domain III) possibly act in a similar way, causing disruption of salt links and impairing domain IIa-domain III interaction.\(^{12}\) Our study adds three additional missense mutations (R490W, R490Q, R489Q) which are associated with normal calpain-3 expression, and suggests that domain III is of crucial importance for protein function.

To better understand the pathogenetic role of calpain-3, we also studied muscle-specific proteins in a prototypic assay. Desmin, α-actinin, β-dystroglycan, and dystrophin did not show any time-dependent loss. On the contrary, nebulin degradation was found only in control muscle where there was normal calpain-3 autocatalytic activity and was not found in any of our eight mutant patients. This could agree with previous studies suggesting an involvement of calpains in cytoskeletal or myofibrillar protein degradation\(^{15,17,18}\), however, we could not experimentally verify if nebulin degradation is directly related to calpain-3 activity or if it is simply a secondary phenomenon.

In conclusion, our study suggests that LGMD2A patients with normal calpain-3 protein expression are relatively frequent (20%) and that a functional test of calpain-3 protein activity is useful to prove the pathogenetic effect of some missense mutations in the domain III of calpain-3.

References


